To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Key facts

Sponsor

Celltrion

Principal Investigator

SungHyun Kim

Celltrion

Intervention

CT-P10(biological)

Enrollment

258 target

Eligibility

18 years · All sexes

Timeline

2015 – 2019

Study locations (1)

• Severance Hospital, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07546760
  A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
  AstraZeneca
• RECRUITINGNCT07528781
  Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume
  Germans Trias i Pujol Hospital
• RECRUITINGPHASE2NCT07029503
  Swedish Cardiac And Renal Failure Study-1
  Karolinska Institutet
• RECRUITINGNCT07154823
  A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
  Tempus AI
• RECRUITINGNCT07328035
  Remission in Adults With Severe Asthma in Thailand
  Thammasat University
• RECRUITINGPHASE3NCT07083154
  GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• RECRUITINGPHASE2NCT07128641
  Odronextamab in Low Tumor Volume Advanced FL
  Gottfried von Keudell, MD PhD
• RECRUITINGPHASE3NCT06911502
  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
  Celgene

See all trials for Follicular lymphoma →